ProCE Banner Activity

Phase I/II TRANSCEND CLL 004: Lisocabtagene Maraleucel (JCAR017) in R/R CLL/SLL After BTK Inhibition Failure

Slideset Download
Conference Coverage
In patients with R/R CLL previously treated with ibrutinib, use of the CD19-directed CAR T-cell therapy lisocabtagene maraleucel was associated a high response rate and undetectable MRD along with low rates of grade ≥ 3 CRS and neurologic events.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro